Document Page: First | Prev | Next | All | Image | This Release | Search
File: 970107_sep96_decls14_0008.txt
Subject: MEDICAL PROD UNDER FDA REG REQUIRED CONSIDER FOR DEPLOYMENT
Unit: OTSG
Parent Organization: HSC
Box ID: BX003201
Folder Title: MEDICAL PRODUCTS UNDER FDA REGULATIONS
Document Number: 930001
Folder Seq #: 930000
2. J-5 Monoclonal Antibody (Cehtoxin)
a. IND # BB-IND-2283, sponsored by Centocor. A separate new
IND will be submitted under sponsorship by the Office of the
surgeon General, US Army.
b. Manufactured by Centocor.
C. Indication: Centoxin is indicated for the treatment of
septic patients with a presumptive diagnosis of gram negative
bacteremia, including those with septic shock. The indication
cited in the IND is the indication intended for use in Operation
Desert Shield.
d. operation Desert Shield status: required immediately.
e. consequences of not using J-5 Monoclonal Antibody in
operation Desert Shield: Increased mortality and morbidity in
burned or wounded soldiers with septicemia or septic shock. This
is not a treatment for biologic warfare threats.
f. Informed consent status: undetermined, pending.
g. Production Availability: 10 September 1990.
h. Point of contact: Dr. Roy, 301-663-7661
Document Page: First | Prev | Next | All | Image | This Release | Search
Document 11 f:/Week-36/BX003201/MEDICAL PRODUCTS UNDER FDA REGULATIONS/medical prod under fda reg required consider for:01029715471415
Control Fields 17
File Room = sep96_declassified
File Cabinet = Week-36
Box ID = BX003201
Unit = OTSG
Parent Organization = HSC
Folder Title = MEDICAL PRODUCTS UNDER FDA REGULATIONS
Folder Seq # = 930000
Subject = MEDICAL PROD UNDER FDA REG REQUIRED CONSIDER FOR
Document Seq # = 930001
Document Date =
Scan Date =
Queued for Declassification = 01-JAN-1980
Short Term Referral = 01-JAN-1980
Long Term Referral = 01-JAN-1980
Permanent Referral = 01-JAN-1980
Non-Health Related Document = 01-JAN-1980
Declassified = 02-JAN-1997